EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers

Peng Gao, Naoki Morita, Reiko Shinkura

Seminars in Immunopathology · 2025

DOI: 10.1007/s00281-024-01027-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Immunopathology, 2025. Verfasst von Peng Gao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-Ku, Tokyo, 113-0…. Hauptthemen laut MEDLINE: Intestinal Mucosa, COVID-19, SARS-CoV-2, Immunity, Mucosal. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AMED, The University of Tokyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To prevent infection, the experience of the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic has led to recognition of the importance of not only vaccines but also the strengthening of mucosal barriers by secretory immunoglobulin A (IgA). Strong mucosal barrier provided by IgA is also possible to prevent allergies and chronic inflammatory conditions in the intestinal tract, since it can protect foreign enemies or antigens at the first line of defense before their invasion. Therefore, it is important to understand the role of IgA antibodies secreted by the mucosa of the body. In this section, we discuss the role of mucosal IgA antibodies in relation to three disease states: control of intestinal microbiota, protection against infection, and allergy. In addition, we provide the evidence in which the quality as well as the quantity of IgA is critical for disease prevention. Therefore, we discuss about novel strategies to enhance mucosal barriers by induction of high-quality IgA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaCOVID-19SARS-CoV-2Immunity, MucosalImmunoglobulin A, SecretoryGastrointestinal MicrobiomeHumansAnimalsImmunoglobulin AHypersensitivity

Stichwörter der Autor:innen

AllergyGut microbiotaImmunoglobulin AMucosal immunityVaccines

Substanzen

Immunoglobulin A, SecretoryImmunoglobulin A

Autor:innen und Institutionen

  • Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-Ku, Tokyo, 113-0032, Japan.
  • Laboratory of Immunology and Infection Control, Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-Ku, Tokyo, 113-0032, Japan. rshinkura@iqb.u-tokyo.ac.jp.

Förderung

  • AMED
  • The University of Tokyo

Zitieren

APA

Gao, P., Morita, N., & Shinkura, R. (2025). Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers. Seminars in Immunopathology. https://doi.org/10.1007/s00281-024-01027-4

Vancouver

Gao P, Morita N, Shinkura R. Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers. Seminars in Immunopathology. 2025. doi:10.1007/s00281-024-01027-4

BibTeX
@article{Gao2025,
  author = {Gao, Peng and Morita, Naoki and Shinkura, Reiko},
  title = {Role of mucosal IgA antibodies as novel therapies to enhance mucosal barriers},
  journal = {Seminars in Immunopathology},
  year = {2025},
  doi = {10.1007/s00281-024-01027-4}
}
Kostenlos starten →